Publications by authors named "A Kurne"

Definitions and measures of asthma control used in clinical trials and practice often vary, as highlighted in the manuscript, "Is asthma control more than just an absence of symptoms? An expert consensus statement". Furthermore, the authors discussed differences between patients and healthcare professionals (HCPs) in terms of understanding and managing asthma. Given these disparities, there is a need for consensus regarding what constitutes well-controlled asthma and, especially, how best it can be measured and recorded.

View Article and Find Full Text PDF

Purpose: Definitions and measures of asthma control used in clinical trials and in clinical practice vary considerably. There is also misalignment between patients and healthcare professionals (HCPs) in terms of understanding and managing asthma control. This study aimed to progress towards a consensus definition of asthma control, and evaluate disparities between HCP and patient perspectives.

View Article and Find Full Text PDF

Background/aim: Neurological involvement (Neuro-Behcet's Disease: NBD) is a rare manifestation of Behcet's Disease (BD) and it is related with significant mortality and morbidity. We aimed to evaluate disease course and outcome of NBD patients registered in Hacettepe University Vasculitis Center (HUVAC) prospective database starting from October 2014.

Methods: Totally, 419 patients (329 of the patients had fulfilled the International Study Group (ISG) criteria and 90 patients were considered as incomplete BD) were recorded as BD to March 2018.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to identify circulating MOG-specific B cells in the blood of patients with MOG antibodies and investigate their relationship with serum anti-MOG antibody levels and epitope specificity.
  • Researchers analyzed blood samples from 21 MOG-antibody-positive patients and 26 controls, finding that a higher frequency of MOG-specific B cells was present in patients, but only about 60% of them tested positive for these B cells.
  • The findings suggest that the quantity of circulating MOG-specific B cells varies significantly among patients and does not correlate with serum MOG antibody levels, indicating potential differences in the sources of these antibodies, which could inform future patient-specific treatments.
View Article and Find Full Text PDF

Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed.

View Article and Find Full Text PDF